Aerie Pharma’s Rhopressa successful in mid-stage study in Japan

Aerie Pharmaceuticals (AERI -1.3%) announces positive results from a Japan-based Phase 2 clinical trial evaluating netarsudil ophthalmic solution 0.02%, branded as Rhopressa in the U.S., for lowering intraocular pressure (IOP) in Japanese patients with open-angle glaucoma or ocular hypertension.

The primary endpoint of mean IOP on day 29 versus placebo was met.

Phase 3 studies are next up.

https://seekingalpha.com/news/3514536-aerie-pharmas-rhopressa-successful-mid-stage-study-japan